BioElectronics Corp. (BIEL: OTC Pink Current) | Clear

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioElectronics Corp. (BIEL: OTC Pink Current) | Clear Channel Business Talk Radio's 'The Traders Network' Interview With Andrew J. Whelan, CEO of BioElectronics Corp Now Available for Online Streaming Clear Channel Business Talk Radio's 'The Traders Network' Interview With Andrew J. Whelan, CEO of BioElectronics Corp Now Available for Online Streaming

Clear Channel Business Talk Radio's 'The Traders Network' Interview With Andrew J. Whelan, CEO of BioElectronics Corp Now Available for Online Streaming

Hosted by Michael Yorba Going Into the Business of Pain and BIEL's Leading Alternatives to Over-the-Counter Drugs Works

DALLAS, TX--(Marketwired - Apr 15, 2014) -  The Traders Network Show Broadcasted live Daily on Clear Channel Business Talk Radio announced today that Andrew Whelan CEO of BioElectronics Corporation ( PINKSHEETS : BIEL ) the maker of advanced consumer medical devices full interview archive and recap in now Available. Hosted Michael Yorba, the two-segment exclusive dives into the business of pain relief, BIEL's opiate alternatives and what the future holds for BioElectronics Corp in 2014

Archived Segment 1: (10min, 01sec)
  http://www.yorbamedia.com/images/stories/audi...14SEG3.mp3
Archived Segment 2: (9min, 35sec)
  http://www.yorbamedia.com/images/stories/audi...14SEG4.mp3
Network: Clear Channel
Station: DFW 1190AM KFXR Dallas-Ft. Worth 
Host: Michael Yorba

Interview Highlights:

In this two segment exclusive with CEO Andrew J. Whelan he talked about how BIEL competitive advantage over traditional over the counter drugs, BIEL market position and how and why the body reacts to pain. "The body is regulated by electrical signals and that essentially their technology modifies those signals to reduce pain, inflammation, and accelerate healing using pulse short wave therapy. Said Whelan

"Our devices send radio signal into tissues, the pulsing causes a muscle response, gets the blood flowing and the blood flow clears out the inflammation and reduces the pain. We have the only real solution to pain. Narcotic drugs don't heal. Our product heals the tissue. Clinically proven pain and inflammation relief at the source. 5x better compared to over-the-counter drugs. Plus our product is 100% safe" 

He went on to talk more about their OTC product The ActiPatch. This therapy is a significant opportunity and presented by one of the most common human ailments, namely, musculoskeletal complaints. This is especially true regarding the substantial market for treating back pain. Additional product opportunities exist to treat sore necks, knees, tennis elbow, heels, and wrist pain.

During the second half of the interview Yorbal asked Whalen to describe the rest of their product line. Along with the Actipatch which is OTC, for Musculoskeletal Pain Relief they have products for foot/heal care, menstrual pain relief, Postoperative Pain & Edema Recovery & Pain Management, and Veterinary Pain Relief.

To hear the entire interview click on the archive links above.

About Clear Channel: Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com .

About Michael Yorba: Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has produced and hosted The Traders Network Show broadcasted live daily on Clear Channel DFW 1190AM KFXR from 1pm - 3pm CT, Monday-Friday.

About The Traders Network Show -- Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It's a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more... shift your thinking and join us as we deliver "tomorrow's ideas today" on Clear Channel's "The Traders Network Show".

About BioElectronics Corporation -- BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com .

A www.1800PublicRelations.com PR Event

Contact:
BIEL
Paul Knopick
+1 (940) 262-3584
pknopick@eandecommunications.com

Press/Media
Matthew Bird
President
MUNCmedia Public Relations
+1 (917) 409-8211
matt.bird@muncmedia.com
www.muncmedia.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading

Top 5 Most Recently Viewed Articles

3Srobotics Breaks Ground with North American Debut

Updated Category News Views 204

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Continue Reading
Uganda Plans Major Spending Cuts and Reduced Borrowing for 2025

Updated Category News Views 912

Uganda's government announced a hefty shift in its fiscal playbook back in 2024, aiming to cut spending by over 20% and slash domestic borrowing by more than half for the upcoming 2025/26 fiscal year. This wasn’t just some routine budgetary tweak; it was a necessary maneuver amidst growing alarm about the nation's spiraling public debt. You know these moves grab...

Continue Reading
Vivos Therapeutics to Share Q1 2025 Results and Updates Soon

Updated Category News Views 257

Vivos Therapeutics Prepares for Q1 2025 Financial Disclosure Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company in the medical devices sector, is gearing up to release its financial results for the first quarter of 2025. This announcement is anticipated to take place following the market's closure on a Thursday in May 2025. The management team is set to hold a...

Continue Reading
Join XBP Global for the Annual Turkey Trot This Thanksgiving

Updated Category News Views 217

XBP Global Welcomes You to the 11th Annual Turkey Trot XBP Global Holdings, Inc. (NASDAQ: XBP) is thrilled to invite the community to the 11th Annual Palisades Turkey Trot, a cherished tradition returning this Thanksgiving morning. Held at Palisades Green, this year's event promises excitement with new 5K and 10K courses that enhance the festive atmosphere of the...

Continue Reading
Market Reaction to CEO Departure and Boot Barn's Strong Quarter

Updated Category News Views 317

Boot Barn Stock Forecast Amid CEO Transition and Solid Performance In the latest developments regarding Boot Barn (NYSE: BOOT), analysts at Craig-Hallum have made notable adjustments to their stock price outlook. The price target has been revised to $160 from a previous $162, maintaining a Hold rating. The adjustments come in light of the company's impressive performance...

Continue Reading